Abstract
We report the case of a 30-year-old woman with severe, prolonged refractory status epilepticus requiring more than 6 months of iatrogenic coma. Opinions on prognosis and clinical management were solicited from a number of experienced neurointensivists and epileptologists at multiple time-points during the clinical course. The ensuing discussion, annotated with references, is presented here. Several experts commented on isolated cases of young patients with encephalitis requiring up to 2–3 months of iatrogenic coma, yet still having good outcomes. Treatments discussed include ketamine, gammaglobulin, plasmapheresis, steroids, adrenocorticotropic hormone, very high-dose phenobarbital, isoflurane, lidocaine, electroconvulsive therapy, ketogenic diet, hypothermia, magnesium, transcranial magnetic stimulation, vagus nerve stimulation, deep brain stimulation, and neurosurgery. The patient eventually suffered a cardiac arrest but was resuscitated as requested by the family. Seizures then stopped, and the patient has remained in a persistent vegetative state since.
Similar content being viewed by others
References
DeBiasi RL, Kleinschmidt-DeMasters BK, Weinberg A, Tyler KL. Use of PCR for the diagnosis of herpesvirus infections of the central nervous system. J Clin Virol 2002;25(Suppl 1):S5-S11.
Hirsch LJ, Claassen J, Mayer SA, Emerson RG. Stimulus-induced rhythmic, periodic, or ictal discharges (SIRPIDs): a common EEG phenomenon in the critically ill. Epilepsia 2004;45(2):109–123.
Chaudhuri A, Kennedy PG. Diagnosis and treatment of viral encephalitis. Postgrad Med J 2002;78(924):575–583.
Johnson RT. Viral Infections of the Nervous System. Philadelphia: Lippincott-Raven; 1998.
Booss J, Esiri MM. Viral Encephalitis: Pathology, Diagnosis and Management. Blackwell Scientific, Oxford, UK, 1986.
Booss J, Esiri MM. Viral Encephalitis in Humans. ASM, Washington, DC, 2003.
Einsiedel L, Kat E, Ravindran J, Slavotinek J, Gordon DL. MR findings in Murray Valley encephalitis. AJNR Am J Neuroradiol 2003;24(7):1379–1382.
Kalita J, Misra UK. Comparison of CT and MRI findings in the diagnosis of Japanese encephalitis. J Neurol Sci 2000; 174:3–8.
Kennedy PG. Viral encephalitis: causes, differential diagnosis, and management. J Neurol Neurosurg Psychiatry 2004;75 (Suppl 1):i10-i15.
Treiman DM, Meyers PD, Walton NY. A comparison of four treatments for generalized convulsive status epilepticus: Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998;17:792–798.
DeLorenzo RJ, Waterhouse EJ, Towne AR, et al. Persistent non-convulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia 1998;39(8):833–840.
Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital propofol, or midazolam: a systematic review. Epilepsia 2002;43(2):146–153.
Sinha S, Naritoku DK. Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology 2000;55(5): 722–724.
Mirski MA, Williams MA, Hanley DF. Prolonged pentobarbital and phenobarbital coma for refractory generalized status epilepticus. Crit Care Med 1995;23(2):400–404.
Crawford TO, Mitchell WG, Fishman LS, Snodgrass SR. Very-high-dose phenobarbital for refractory status epilepticus in children. Neurology 1988;38(7):1035–1040.
Krishnamurthy KB, Drislane FW. Depth of EEG suppression and outcome in barbiturate anesthetic treatment for refractory status epilepticus. Epilepsia 1999;40(6):759–762.
Krishnamurthy KB, Drislane FW. Relapse and survival after barbiturate anesthetic treatment of refractory status epilepticus. Epilepsia 1996;37(9):863–867.
Sahin M, Menache CC, Holmes GL, Riviello JJ, Jr. Prolonged treatment for acute symptomatic refractory status epilepticus: outcome in children. Neurology 2003;61(3):398–401.
Chinnery PF, Turnbull DM. Clinical features, investigation, and management of patients with defects of mitochondrial DNA. J Neurol Neurosurg Psychiatry 1997;63:559–563.
Lamps LW, Scott MA. Cat-scratch disease: historic, clinical, and pathologic perspectives. Am J Clin Pathol 2004;121(Suppl):S71-S80.
Singhal AB, Newstein MC, Budzik R, et al. Diffusion-weighted magnetic resonance imaging abnormalities in Bartonella encephalopathy. J Neuroimaging 2003;13(1):79–82.
Mirsattari SM, Sharpe MD, Young GB. Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and desflurane. Arch Neurol 2004;61(8):1254–1259.
Kofke WA, Young RS, Davis P, et al. Isoflurane for refractory status epilepticus: a clinical series. Anesthesiology 1989;71(5):653–659.
Jensen NF, Fiddler DS, Striepe V. Anesthetic considerations in porphyrias. Anesth Analg 1995;80(3):591–599.
Borris DJ, Bertram EH, Kapur J. Ketamine controls prolonged status epilepticus. Epilepsy Res 2000;42:117–122.
Bleck TP. Refractory status epilepticus in 2001. Arch Neurol 2002;59(2):188–189.
Williams AJ, Tortella FC, Lu XM, Moreton JE, Hartings JA. Antiepileptic drug treatment of nonconvulsive seizures induced by experimental focal brain ischemia. J Pharmacol Exp Ther 2004; 311(1):220–227.
Clifford DB, Olney JW, Benz AM, Fuller TA, Zorumski CF. Ketamine, phencyclidine, and MK-801 protect against kainic acid-induced seizure-related brain damage. Epilepsia 1990;31:382–390.
Sheth RD, Gidal BE, Refractory status epilepticus: response to ketamine. Neurology 1998;51(6):1765–1766.
Mewasingh LD, Sekhara T, Aeby A, Christiaens FJ, Dan B. Oral ketamine in paediatric non-convulsive status epilepticus. Seizure 2003;12(7):483–489.
Brunson KL, Avishai-Elinder S, Baram TZ. ACTH treatment of infantile spasms: Mechanisms of its effects in modulation of neuronal excitability. Int Rev Neurobiol 2002;49:185–197.
Thieben M, Lennon V, Boeve B, Aksamit A, Keegan M, Vernino S. Potentially reversible autoimmune limbic encephalitis with potassium channel antibody. Neurology 2004;62(7):1177–1182.
Vincent A, Buckley C, Schott J, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004;127(Pt3):701–712.
Newsom-Davis J, Buckley C, Clover L, Hart I, Maddison P, Tuzum E, Vincent A. Autoimmune disorders of neuronal potassium channels. Ann NY Acad Sci 2003;998:202–210.
Villani F, Avanzini G. The use of immunoglobulins in the treatment of human epilepsy. Neurol Sci 2002;23(Suppl 1):S33-S37.
Emmi L, Chiarini F. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci 2002;23(Suppl 1):S1-S8. Review.
Vastola EF, Homan R, Rosen A. Inhibition of focal seizures by moderate hypothermia. A clinical and experimental study. Arch Neurol 1969;20(4):430–439.
Bassin S, Smith TL, Bleck TP. Clinical review: status epilepticus. Crit Care 2002;6(2):137–142.
Beeson D. Autoantibodies in the CNS: Encephalopathy and potassium channelopathy. Neurology 2004;52:1040–1041.
Claassen J, Hirsch LJ, Emerson RG, Bates JE, Thompson TB, Mayer SA. Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus. Neurology 2001; 57(6):1036–1042.
Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 2002;59(2):205–210.
Sibai BM. Diagnosis, prevention, and management of eclampsia. Obstet Gynecol 2005;105(2):402–410.
Iannetti P, Spalice A, Parisi P. Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 2005;46(6):967–969.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Robakis, T.K., Hirsch, L.J. Literature review, case report, and expert discussion of prolonged refractory status epilepticus. Neurocrit Care 4, 35–46 (2006). https://doi.org/10.1385/NCC:4:1:035
Issue Date:
DOI: https://doi.org/10.1385/NCC:4:1:035